Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Haematologica
Egile Nagusiak: Michallet, Anne-Sophie, Aktan, Melih, Hiddemann, Wolfgang, Ilhan, Osman, Johansson, Peter, Laribi, Kamel, Meddeb, Balkis, Moreno, Carol, Raposo, João, Schuh, Anna, Ünal, Ali, Widenius, Tom, Bernhardt, Alf, Kellershohn, Kerstin, Messeri, Dimitri, Osborne, Stuart, Leblond, Véronique
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865431/
https://ncbi.nlm.nih.gov/pubmed/29419437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.170480
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak